Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.25
PRGO's Cash to Debt is ranked higher than
50% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.19 vs. PRGO: 0.25 )
PRGO' s 10-Year Cash to Debt Range
Min: 0   Max: 18.02
Current: 0.25

0
18.02
Equity to Asset 0.63
PRGO's Equity to Asset is ranked higher than
72% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. PRGO: 0.63 )
PRGO' s 10-Year Equity to Asset Range
Min: 0.35   Max: 0.75
Current: 0.63

0.35
0.75
F-Score: 4
Z-Score: 2.94
M-Score: -1.90
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 13.97
PRGO's Operating margin (%) is ranked higher than
83% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.96 vs. PRGO: 13.97 )
PRGO' s 10-Year Operating margin (%) Range
Min: -32.27   Max: 19.18
Current: 13.97

-32.27
19.18
Net-margin (%) 5.06
PRGO's Net-margin (%) is ranked higher than
70% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.39 vs. PRGO: 5.06 )
PRGO' s 10-Year Net-margin (%) Range
Min: -34.47   Max: 12.66
Current: 5.06

-34.47
12.66
ROE (%) 3.36
PRGO's ROE (%) is ranked higher than
65% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.37 vs. PRGO: 3.36 )
PRGO' s 10-Year ROE (%) Range
Min: -62.64   Max: 25.88
Current: 3.36

-62.64
25.88
ROA (%) 1.97
PRGO's ROA (%) is ranked higher than
67% of the 814 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.13 vs. PRGO: 1.97 )
PRGO' s 10-Year ROA (%) Range
Min: -28.65   Max: 11.48
Current: 1.97

-28.65
11.48
ROC (Joel Greenblatt) (%) 36.50
PRGO's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.57 vs. PRGO: 36.50 )
PRGO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -70.75   Max: 53.06
Current: 36.5

-70.75
53.06
Revenue Growth (%) 6.00
PRGO's Revenue Growth (%) is ranked higher than
71% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. PRGO: 6.00 )
PRGO' s 10-Year Revenue Growth (%) Range
Min: -5.5   Max: 17.5
Current: 6

-5.5
17.5
EBITDA Growth (%) 8.10
PRGO's EBITDA Growth (%) is ranked higher than
74% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. PRGO: 8.10 )
PRGO' s 10-Year EBITDA Growth (%) Range
Min: -25.1   Max: 40.1
Current: 8.1

-25.1
40.1
EPS Growth (%) -21.40
PRGO's EPS Growth (%) is ranked higher than
61% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. PRGO: -21.40 )
PRGO' s 10-Year EPS Growth (%) Range
Min: -66.2   Max: 210.7
Current: -21.4

-66.2
210.7
» PRGO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

PRGO Guru Trades in Q3 2013

Jeremy Grantham 12,900 sh (New)
George Soros 19,000 sh (New)
Steven Cohen 305,298 sh (New)
Jim Simons 453,270 sh (+3655.34%)
Paul Tudor Jones 3,700 sh (+68.18%)
David Rolfe 1,393,714 sh (+34.46%)
Ruane Cunniff 1,781,038 sh (+2.44%)
Ken Fisher 583,782 sh (+0.55%)
Mariko Gordon 29,473 sh (-0.14%)
John Keeley 34,857 sh (-1.32%)
Ron Baron 203,294 sh (-36.19%)
» More
Q4 2013

PRGO Guru Trades in Q4 2013

Louis Moore Bacon 2,131 sh (New)
Eric Mindich 106,904 sh (New)
Robert Bruce 9,926 sh (New)
David Rolfe 1,459,279 sh (+4.7%)
Jim Simons 471,810 sh (+4.09%)
Steven Cohen Sold Out
Jeremy Grantham Sold Out
George Soros Sold Out
Mariko Gordon 29,300 sh (-0.59%)
Ruane Cunniff 1,763,823 sh (-0.97%)
John Keeley 34,289 sh (-1.63%)
Paul Tudor Jones 3,600 sh (-2.7%)
Ken Fisher 499,419 sh (-14.45%)
Ron Baron 126,830 sh (-37.61%)
» More
Q1 2014

PRGO Guru Trades in Q1 2014

Steven Cohen 72,588 sh (New)
Ray Dalio 62,322 sh (New)
Jeremy Grantham 17,900 sh (New)
George Soros 85,000 sh (New)
David Rolfe 1,494,779 sh (+2.43%)
Vanguard Health Care Fund 3,094,152 sh (unchged)
Robert Bruce 9,926 sh (unchged)
Eric Mindich Sold Out
Louis Moore Bacon Sold Out
Jim Simons Sold Out
Ruane Cunniff 1,718,939 sh (-2.54%)
Mariko Gordon 28,520 sh (-2.66%)
Ken Fisher 483,860 sh (-3.12%)
John Keeley 28,741 sh (-16.18%)
Ron Baron 77,865 sh (-38.61%)
Paul Tudor Jones 1,800 sh (-50%)
» More
Q2 2014

PRGO Guru Trades in Q2 2014

Alan Fournier 472,300 sh (New)
Paul Tudor Jones 150,000 sh (+8233.33%)
David Rolfe 1,742,399 sh (+16.57%)
John Keeley 30,593 sh (+6.44%)
Vanguard Health Care Fund 3,210,552 sh (+3.76%)
Ron Baron 78,373 sh (+0.65%)
Ken Fisher 486,226 sh (+0.49%)
Robert Bruce 9,926 sh (unchged)
Steven Cohen 15,000 sh (unchged)
Ray Dalio Sold Out
Jeremy Grantham Sold Out
George Soros Sold Out
Mariko Gordon 28,494 sh (-0.09%)
Ruane Cunniff 1,717,063 sh (-0.11%)
» More
» Details

Insider Trades

Latest Guru Trades with PRGO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 Sold Out 0.13%$126.87 - $157.2 $ 145.783%0
Ray Dalio 2014-06-30 Sold Out 0.08%$126.87 - $157.2 $ 145.783%0
George Soros 2014-03-31 New Buy0.13%$145.74 - $167.6 $ 145.78-8%85000
Ray Dalio 2014-03-31 New Buy0.08%$145.74 - $167.6 $ 145.78-8%62322
Ron Baron 2014-03-31 Reduce -38.61%0.03%$145.74 - $167.6 $ 145.78-8%77865
Robert Bruce 2013-12-31 New Buy0.43%$125.11 - $156.88 $ 145.781%9926
Ron Baron 2013-12-31 Reduce -37.61%0.04%$125.11 - $156.88 $ 145.781%126830
George Soros 2013-12-31 Sold Out 0.03%$125.11 - $156.88 $ 145.781%0
Ron Baron 2013-09-30 Reduce -36.19%0.07%$116.83 - $134.23 $ 145.7817%203294
George Soros 2013-09-30 New Buy0.03%$116.83 - $134.23 $ 145.7817%19000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Perrigo Co PLC

David Rolfe Comments on Perrigo - Jan 27, 2014

During the quarter, Perrigo (PRGO) announced strong September quarter adjusted earnings growth of 20%.  We say “adjusted” because the Company incurred what we believe are non-recurring charges related to the recent purchase of Elan Corporation, which is a branded-drug company domiciled in Ireland.  Upon the closing of this purchase, Perrigo has “re-domiciled” itself in Ireland, with an effective tax rate meaningfully below what they were subjected to in the U.S.  Given that the Company actively pursues a strategy of inorganic growth as much as it pursues organic growth - having acquired six new businesses over the past 18 months (including Elan) - we expect that this new tax structure should make future acquisitions, particularly those U.S. based businesses, much more attractive.  Further, Perrigo’s core business, which includes private-label over-the-counter (OTC) pharmaceuticals and infant formula, drove much of the year-over-year growth.  The Company’s unrivaled scale in manufacturing and marketing of store-branded offerings continues to enable retailers to mimic the value proposition of OTC pharmaceuticals and infant formula.  This “store-brand conversion” is a multi-year trend that we expect will continue for the foreseeable future as consumers continue to become more value-conscious, yet more comfortable with store-brand quality that Perrigo helps engineer. 

 

From David Rolfe (Trades, Portfolio)’s Wedgewood Partners Fourth Quarter 2013 Commentary.

Check out David Rolfe latest stock trades

Meridian Funds Comments on Perrigo - Aug 28, 2013

Perrigo (PRGO) is a global manufacturer of over-the-counter (OTC) store brand and generic prescription pharmaceuticals, infant formulas, nutritional products and active pharma ingredients. The company is the dominant player in the OTC drug market with the largest distribution network and broadest range of product offerings. The OTC store brands have increased their market share by about 1-2% annually at the expense of national name product given their superior value proposition to both the consumer and retailers. Perrigo has numerous growth drivers over the next few years including the continued penetration of OTC store brands and introduction of new product categories. The stock sells at a reasonable valuation, in our opinion, given the company's strong management team, financial returns and long-term growth prospects.

From Meridian Funds's commentary for the quarter ended June 30, 2013.


Check out Meridian Funds latest stock trades

Baron Funds Comments on Perrigo - Feb 06, 2013

Shares of Perrigo Co. (PRGO), the largest manufacturer of store brand, over-thecounter pharmaceutical products, fell after quarterly revenues in its Nutritionals segment, which includes private label infant formula and vitamins, fell short of expectations. We believe that the shortfall was explained by a combination of short term factors, and we are optimistic that the company's infant formula revenues are poised for strong growth, particularly in China, where its points of distribution are increasing.We are also encouraged by Perrigo's recent accretive acquisition of Sergeant's Pet Care, through which the company entered the market for private-label pet medications.

From Baron Funds' fourth quarter letter.


Check out Ron Baron latest stock trades

Top Ranked Articles about Perrigo Co PLC

David Rolfe Comments on Perrigo
During the quarter, Perrigo (PRGO) announced strong September quarter adjusted earnings growth of 20%.  We say “adjusted” because the Company incurred what we believe are non-recurring charges related to the recent purchase of Elan Corporation, which is a branded-drug company domiciled in Ireland.  Upon the closing of this purchase, Perrigo has “re-domiciled” itself in Ireland, with an effective tax rate meaningfully below what they were subjected to in the U.S.  Given that the Company actively pursues a strategy of inorganic growth as much as it pursues organic growth - having acquired six new businesses over the past 18 months (including Elan) - we expect that this new tax structure should make future acquisitions, particularly those U.S. based businesses, much more attractive.  Further, Perrigo’s core business, which includes private-label over-the-counter (OTC) pharmaceuticals and infant formula, drove much of the year-over-year growth.  The Company’s unrivaled scale in manufacturing and marketing of store-branded offerings continues to enable retailers to mimic the value proposition of OTC pharmaceuticals and infant formula.  This “store-brand conversion” Read more...
Weekly Insider Sells Highlight: ROC, PRGO, JCI, TEL, DISH
According to GuruFocus Insider Data, the largest insider sells during the past week were: Rockwood Holdings Inc., Perrigo Company, Johnson Controls Inc., TE Connectivity Ltd. and DISH Network Corp. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 88.20
PRGO's P/E(ttm) is ranked higher than
68% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 41.40 vs. PRGO: 88.20 )
PRGO' s 10-Year P/E(ttm) Range
Min: 13.36   Max: 93.87
Current: 88.2

13.36
93.87
P/B 2.24
PRGO's P/B is ranked higher than
80% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.26 vs. PRGO: 2.24 )
PRGO' s 10-Year P/B Range
Min: 2.01   Max: 5.96
Current: 2.24

2.01
5.96
P/S 4.07
PRGO's P/S is ranked higher than
69% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. PRGO: 4.07 )
PRGO' s 10-Year P/S Range
Min: 0.95   Max: 4.42
Current: 4.07

0.95
4.42
PFCF 33.90
PRGO's PFCF is ranked higher than
89% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. PRGO: 33.90 )
PRGO' s 10-Year PFCF Range
Min: 10.63   Max: 86.68
Current: 33.9

10.63
86.68
EV-to-EBIT 38.68
PRGO's EV-to-EBIT is ranked higher than
74% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.26 vs. PRGO: 38.68 )
PRGO' s 10-Year EV-to-EBIT Range
Min: 10.3   Max: 45.3
Current: 38.68

10.3
45.3
PEG 5.39
PRGO's PEG is ranked higher than
85% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. PRGO: 5.39 )
PRGO' s 10-Year PEG Range
Min: 0.67   Max: 4.33
Current: 5.39

0.67
4.33
Shiller P/E 45.45
PRGO's Shiller P/E is ranked higher than
81% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 97.53 vs. PRGO: 45.45 )
PRGO' s 10-Year Shiller P/E Range
Min: 25   Max: 3968
Current: 45.45

25
3968
Current Ratio 2.37
PRGO's Current Ratio is ranked higher than
72% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. PRGO: 2.37 )
PRGO' s 10-Year Current Ratio Range
Min: 1.52   Max: 2.98
Current: 2.37

1.52
2.98
Quick Ratio 1.79
PRGO's Quick Ratio is ranked higher than
72% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. PRGO: 1.79 )
PRGO' s 10-Year Quick Ratio Range
Min: 0.89   Max: 2.87
Current: 1.79

0.89
2.87

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.28
PRGO's Dividend Yield is ranked lower than
89% of the 493 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.34 vs. PRGO: 0.28 )
PRGO' s 10-Year Dividend Yield Range
Min: 0.22   Max: 1.23
Current: 0.28

0.22
1.23
Dividend Payout 0.22
PRGO's Dividend Payout is ranked higher than
89% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.21 vs. PRGO: 0.22 )
PRGO' s 10-Year Dividend Payout Range
Min: 0.07   Max: 0.23
Current: 0.22

0.07
0.23
Dividend growth (3y) 12.60
PRGO's Dividend growth (3y) is ranked higher than
87% of the 360 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. PRGO: 12.60 )
PRGO' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 49.8
Current: 12.6

0
49.8
Yield on cost (5-Year) 0.55
PRGO's Yield on cost (5-Year) is ranked lower than
77% of the 500 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.42 vs. PRGO: 0.55 )
PRGO' s 10-Year Yield on cost (5-Year) Range
Min: 0.4   Max: 2.24
Current: 0.55

0.4
2.24
Share Buyback Rate -7.30
PRGO's Share Buyback Rate is ranked higher than
63% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -1.10 vs. PRGO: -7.30 )
PRGO' s 10-Year Share Buyback Rate Range
Min: 1.7   Max: -9.8
Current: -7.3

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.61
PRGO's Price/DCF (Projected) is ranked higher than
89% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.71 vs. PRGO: 1.61 )
PRGO' s 10-Year Price/DCF (Projected) Range
Min: 1   Max: 2.31
Current: 1.61

1
2.31
Price/Median PS Value 2.16
PRGO's Price/Median PS Value is ranked higher than
57% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.24 vs. PRGO: 2.16 )
PRGO' s 10-Year Price/Median PS Value Range
Min: 0.33   Max: 2.16
Current: 2.16

0.33
2.16
Price/Peter Lynch Fair Value 4.06
PRGO's Price/Peter Lynch Fair Value is ranked higher than
87% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. PRGO: 4.06 )
PRGO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.78   Max: 4.07
Current: 4.06

0.78
4.07
Earnings Yield (Greenblatt) 2.60
PRGO's Earnings Yield (Greenblatt) is ranked higher than
64% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. PRGO: 2.60 )
PRGO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.2   Max: 9.8
Current: 2.6

2.2
9.8
Forward Rate of Return (Yacktman) 23.11
PRGO's Forward Rate of Return (Yacktman) is ranked higher than
92% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.19 vs. PRGO: 23.11 )
PRGO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.8   Max: 35.6
Current: 23.11

1.8
35.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:PIG.Germany, PRGO.Israel
Perrigo Company was established in 1887. It is a healthcare supplier that develops, manufactures and distributes over-the-counter and generic prescription (Rx) pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products. The Company is a manufacturer of OTC pharmaceutical products for the store brand market. The Company has four reportable segments namely Consumer Healthcare, Nutritionals, Rx Pharmaceuticals and API. In addition, the Company also operates Israel Pharmaceutical and Diagnostic Products operating segment The Consumer Healthcare segment includes the Company's U.S., U.K. and Mexico operations supporting the sale of OTC pharmaceutical and nutritional products. Its product categories include analgesic, cough/cold/allergy/sinus, gastrointestinal, smoking cessation, first aid and vitamin and nutritional supplement products. The Nutritionals segment develops, manufactures, markets and distributes store brand infant and toddler formula products, infant and toddler foods, vitamin, mineral and dietary supplement ('VMS') products, and oral electrolyte solution ('OES') products to retailers, distributors and consumers mainly in the U.S., Canada, Mexico and China. The Rx Pharmaceuticals segment develops, manufactures and markets a portfolio of generic prescription drugs in the U.S. This portfolio is comprised of products of topicals including creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquid suspensions and solutions. It develops manufactures and markets API used worldwide by the generic drug industry and branded pharmaceutical companies. Certain of these ingredients are used in its own pharmaceutical products. Its main manufacturing facilities are located in the U.S. and Israel. Among Perrigo's competitors in the topical generics market are Actavis U.S., Fougera, Paddock Laboratories, Sandoz, Taro Pharmaceutical, Teva Pharmaceutical, and Triax Pharmaceuticals, as well as brand-name pharmaceutical companies where the Company offers a generic equivalent. The Company is subject to various environmental laws and regulations.
» More Articles for NYSE:PRGO

Headlines

Articles On GuruFocus.com
David Rolfe's Wedgewood Partners Q2 2014 Commentary Jul 15 2014 
David Rolfe Comments on Perrigo Jan 27 2014 
Weekly Insider Sells Highlight: ROC, PRGO, JCI, TEL, DISH Dec 16 2013 
Weekly CFO Sells Highlight: FleetCor Technologies Inc., Facebook Inc., Perrigo Company, WellPoint In Dec 15 2013 
Three Companies Gain in Bargain Portfolio Sep 26 2013 
Meridian Funds Comments on Perrigo Aug 28 2013 
Meridian Funds' Second Quarter 2013 Commentary Aug 28 2013 
The Truth About the Impact of Dividend Reinvesting Apr 10 2013 
Baron Funds Comments on Perrigo Feb 06 2013 
recent drop- guru pi Jan 21 2013 


More From Other Websites
Wife of convicted ex-SAC employee petitions to keep cash, home Oct 15 2014
Perrigo Animal Health Receives SQF Certification Oct 14 2014
Generics Firms Step Up Their Game In Branded Drugs Oct 06 2014
U.S. SEC to decide if investors share in $600 mln SAC settlement Oct 03 2014
Perrigo Sells Some Assets to Imago Pharmaceuticals Oct 03 2014
Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016,... Oct 02 2014
Perrigo Company plc Announces Extension of Exchange Offer for Its 1.30% Senior Notes Due 2016, 2.30%... Oct 01 2014
AMAG Up on Roughly $1B deal with Lumara to Widen Portfolio Sep 30 2014
Akorn Upgraded On Strong Generic Drug Trends Sep 29 2014
Amag, Perrigo Buy Lumara in Two-Step Deal Valued at $1.1B Sep 29 2014
Lumara Health to sell assets to AMAG, Perrigo for $757 million Sep 29 2014
Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals Sep 29 2014
Lumara Health™ to be Acquired in Two Separate Transactions for up to $1.107 Billion Sep 29 2014
Perrigo Enters New Therapeutic Category With The Acquisition Of Women's Health Product Portfolio... Sep 29 2014
Multiple Sclerosis Drugs Could Transform Market Again Sep 26 2014
#PreMarket Primer: Wednesday, September 10: Dollar General Gets Aggressive Sep 10 2014
SAC's Martoma gets 9 years prison for insider trading Sep 08 2014
SAC's Martoma gets 9 years prison for insider trading Sep 08 2014
SAC's Martoma gets 9 years prison for record insider trading scheme Sep 08 2014
U.S. judge won't toss insider trading conviction of SAC's Martoma Sep 04 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK